SunWay Biotech Co

SunWay Biotech Co EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of SunWay Biotech Co (1271.TWO) as of Oct 19, 2026 is 2.33 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 3.72 % — a change of -37.22% (lower).

EBIT/Assets

2.33 %

YoY

-37.22%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of SunWay Biotech Co is 2025 2.33 % . Operating Income to Assets Ratio (EBIT/Assets) of SunWay Biotech Co was 2024 3.72 % . It decreases by -37.22% lower compared to the previous year.

The SunWay Biotech Co EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2019
13.26 TWD
Jan 1, 2020
24.63 TWD
Jan 1, 2021
27.60 TWD
Jan 1, 2022
8.20 TWD
Jan 1, 2023
1.43 TWD
Jan 1, 2024
3.72 TWD
Jan 1, 2025
2.33 TWD
The SunWay Biotech Co EBIT/Assets history
YEAREBIT/AssetsYoY
2.33 %-37.22%
3.72 %+159.14%
1.43 %-82.51%
8.20 %-70.28%
27.60 %+12.07%
24.63 %+85.70%
13.26 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SunWay Biotech Co Stock analysis

What does SunWay Biotech Co do? SunWay Biotech Co Ltd is a pharmaceutical company based in Taipei City, Taiwan. The company went public on January 18, 2021, with its ticker listed as 1271.TWO and ISIN TW0001271005. SunWay Biotech focuses on the research, development, manufacture, and sale of health food products, particularly those derived from red yeast. The company's primary products include Lactobacillus paracasei subsp. paracasei NTU 101 and Monascus purpureus NTU 568, which are marketed for their health benefits. These products are designed to support digestive health, improve the bacterial ecology of the digestive tract, regulate immunity, and address allergies. SunWay Biotech operates in both domestic and international markets, distributing its products globally. The company's website is https://sunway.cc/, where further information about its offerings can be found. SunWay Biotech is categorized under the Health Care sector, specifically within the Pharmaceuticals industry. The company's business model centers on the production and sale of health food supplements, emphasizing natural ingredients and their functional benefits. It does not provide information on specific founding year, key personnel, or financial figures beyond its IPO date. The company's activities are strictly limited to the development and distribution of health food products without mention of additional services or product lines. SunWay Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SunWay Biotech Co stock

Operating Income to Assets Ratio (EBIT/Assets) of SunWay Biotech Co is 2.33 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of SunWay Biotech Co changed from 3.72 % to 2.33 %, representing a -37.22% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) SunWay Biotech Co since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s SunWay Biotech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — SunWay Biotech Co

All Key Metrics — SunWay Biotech Co